Application of the Diabetes Algorithm to a Patient

Similar documents
Application of the Diabetes Algorithm to Patients

Application of the Diabetes Algorithm to a Patient

A Practical Approach to the Use of Diabetes Medications

Complete this CE activity online at ProCE.com/InsulinPart2

Type 2 Diabetes Mellitus Insulin Therapy 2012

Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes

UKPDS: Over Time, Need for Exogenous Insulin Increases

Update on Insulin-based Agents for T2D

Timely!Insulinization In!Type!2! Diabetes,!When!and!How

CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia

Update on Insulin-based Agents for T2D. Harry Jiménez MD, FACE

The Many Faces of T2DM in Long-term Care Facilities

Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM

Joslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function

Your Chart Review Data. Lara Zisblatt, MA Assistant Director Continuing Medical Education Boston University School of Medicine

Objectives 2/13/2013. Figuring out the dose. Sub Optimal Glycemic Control: Moving to the Appropriate Treatment

Insulin Intensification: A Patient-Centered Approach

RISK FACTORS OR COMPLICATIONS AND RECOMMENDED TREATMENT GOALS AND FREQUENCY OF EVALUATION FOR ADULTS WITH DIABETES

RCHC Clinical Guidelines Type 2 Diabetes; Adults

Type 2 Diabetes Performance Improvement Initiative: Chart Reviews. Lara Zisblatt Boston University School of Medicine Boston, MA

Participants in the Program

Diabetes Overview. How Food is Digested

Insulin Initiation, titration & Insulin switch in the Primary Care-KISS

Comprehensive Diabetes Treatment

Optimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification

Self-Monitoring Blood Glucose (SMBG) Frequency & Pattern Tool

Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone

Multiple Factors Should Be Considered When Setting a Glycemic Goal

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

INSULIN THERAPY. Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital

Glycemic Control IU Health Diabetes Centers

Adult Diabetes Clinician Guide NOVEMBER 2017

ABFM Diabetes SAM Part 4

INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION

Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes

Using Insulin in the Primary Care Setting: Interactive Cases

Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010

Insulin Initiation and Intensification. Disclosure. Objectives

APPENDIX American Diabetes Association. Published online at

Antihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014

Investigators, study sites Multicenter, 35 US sites. Coordinating Investigator: Richard Bergenstal, MD

nocturnal hypoglycemia percentage of Hispanics in the insulin glargine than NPH during forced patients who previously This study excluded

LOW SUGAR: CAUSES, COMPLICATIONS AND MANAGEMENT OF HYPOGLYCEMIA

Case study: Adult with uncontrolled type 2 diabetes of long duration and cardiovascular disease

Clinical Cases in Diabetes Management. Joseph Cook D.O.

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)

Metabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology

Role of SMBG in Non-Insulin Treated Subjects with T2DM Richard M. Bergenstal, MD

Individualizing Therapy int2dm With Insulin

Have participants measure their blood pressure daily at a standard time for two weeks. Obtain BP values from participant (fax, call, , mail).

Current Clinical Practice Guideline for Diabetes Management

Initiation and Titration of Insulin in Diabetes Mellitus Type 2

CURRENT CONTROVERSIES IN DIABETES CARE

Diabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items

Treat-to-Target Tools

Case Report Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes Mellitus

Clinical Study Synopsis

DEMYSTIFYING INSULIN THERAPY

Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes

It Happens Even in Type 2! When to Start Thinking Seriously About Hypoglycemia

Type 2 Diabetes Mellitus 2011

Breaking the Cycle: Using Incretin-Based Therapies to Overcome Clinical Inertia in Type 2 Diabetes

AACE COMPREHENSIVE DIABETES MANAGEMENT ALGORITHM

Insulin and Post Prandial

Guidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010

Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol

Reviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate

5/16/2018. Insulin Workshop. Disclosures to Participants. Learning Objectives. This presentation will cover the following learning objectives:

Diabetes Self-Management Education Record

Personal Diabetes Passport

Common Diabetes-related Terms

CURRENT ISSUES IN DIABETES MANAGEMENT. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test. Diagnosis of Diabetes 2013

Analyzing Glucose Data

More Than Just the Numbers:

American Diabetes Association 2018 Guidelines Important Notable Points

4/10/2015. Foundations to Managing Inpatient Hyperglycemia. Learning Objectives

Addressing Addressing Challenges in Type 2 Challenges in Type 2 Diabetes Diabetes Speaker:

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

Learning Objectives. Outline 4/3/2018. Treatment Strategies to Maximize the Value of Diabetes Medications

Advances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies. Module D

Efficacy/pharmacodynamics: 85 Safety: 89

PHYSICIANS INTERACTIVE PARTICIPANT GUIDE

Case Study. Patient Profile. Baseline Report - Daily Patterns. Insights

DM in OPD for Internist. Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital 28 Oct 2013

TEAMcare Treat-to-Target Tools

Diabetes Mellitus Type 2

2/4/13. Insulin Dosing. Insulin Dosing. Insulin Dosing. Insulin Dosing. Insulin Dosing. Insulin Dosing

Chief of Endocrinology East Orange General Hospital

Diabetes Mellitus in Older Adults. Presenter Disclosure Information

9/28/2012. Sponsored By: NDSU College of Pharmacy, Nursing and Allied Sciences

The importance of continuous glucose monitoring when transitioning a patient from insulin detemir to U-500R

Reason for referral: provide patient education on management of hypoglycemia and glucose monitor

Clinical Practice Guidelines

Progressive Loss of β-cell Function in T2DM

Clinical Practice Guideline Key Points

Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy

Diabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE

Vipul Lakhani, MD Oregon Medical Group Endocrinology

Transcription:

Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent real patients and are designed to show how different physicians approach patient management. This information serves as a springboard for discussion, and does not imply AACE s endorsement of any specific treatment approach.

Case #3 John John is a 62 year-old African American man, with type 2 diabetes, diagnosed 10 years ago He works as a electrician and has irregular meal times He tries to avoid sweets He smokes 1 pack a day and drinks 1-2 beers a night He is 3 months late on his 6-month checkup He has a history of CAD, depression, and hypertension CAD = coronary artery disease

Case #3, John Diabetes Checkup John reports feeling anxious sometimes for no clear reason; at these times, his hands become clammy and tremble and he becomes sweaty Height: 6 2, Weight: 234 lbs, BMI: 30 kg/m 2 BP 184/100 mm Hg, HR 90 bpm ROS negative except poor glucose control BMI = body mass Index; BP = blood pressure; HR = heart rate; lb = pounds; ROS = review of systems

A1C = glycated hemoglobin; ASA = aspirin; BID = twice daily; BMI = body mass Index; BP = blood pressure; CGM = continuous glucose monitoring; egrf = estimated glomerular Current labs: - A1C: 9.4%; Case #3, John Diabetes Checkup - Home blood glucose ranges: FPG 180-200 mg/dl; premeal 200-250 mg/dl Serum creatinine: 2.3 mg/dl, LFTs normal, urine albumin: 92 mg/g creatinine, TC 153 mg/dl, LDL 70 mg/dl, HDL 41 mg/dl, TG 225 mg/dl egfr 44 ml/min Current medications: Metformin, 1000 mg BID Glimepiride, 4 mg QD Sitagliptin, 100 mg QD ASA, 81 mg QD Benazepril, 40 mg QD Simvastatin, 40 mg QD Escitalopram, 10 mg QD

What do John s symptoms of anxiety, trembling, sweating, and clammy hands suggest? (a) (b) (c) (d) Hyperglycemia Hypoglycemia Hypothyroidism GERD? GERD = gastroesophageal reflux disease

H.Rettinger, M.D. Symptoms of Hypoglycemia Are Like Falling in Love for the First You get nervous and jittery You get hot and sweaty Time! Your heart starts beating rapidly And last you want to say something intelligent, but only gibberish comes out!

John s Self-monitoring Blood Glucose Download Frequent episodes of hypoglycemia due to sulfonylurea and chronic kidney disease

What would you do next to adjust John s treatment? (a) (b) (c) (d) Stop metformin and add basal insulin Stop glimepiride and add basal insulin Only continue sitagliptin and add basal insulin Stop all oral medications and start basal/bolus insulin?

Road Map To Achieve Glycemic Goals: John s A1C = 9.4% AGI = alpha glucosidase inhibitor; BG = blood glucose; DPP-4 = dipeptidyl peptidase 4; FBG = fasting blood glucose; GLP = glucagon-like peptide-1; MET = metformin; NAFLD = John is already on triple therapy with A1C still >9%; likely having hypoglycemia He may continue sitagliptin, as this will decrease potential need for bolus insulin and reduce post-prandial glycemic variability; however, due to his increased Cr, his sitagliptin dose should be reduced to 50 mg Basal insulin should be initiated Hypoglycemia was driven by the SU and that is why it was stopped Garber AJ, et al. Endocr Pract. 2017, doi:10.4158/ep161682.cs.

How will you manage John s current BP? John s current BP is 182/100 mm Hg, pulse 90: how will you approach management of his BP? (a) Counsel on diet and lifestyle changes (b) Start John on a beta-blocker, carvedilol 6.25 mg BID (given known CAD, rapid pulse) and schedule a follow up visit in 1 week (c) Recommend reductions in his alcohol consumption (d) Recommend a smoking cessation program (e) All of the above? BID = twice daily; BP = blood pressure; CAD = coronary artery disease; mg = milligram; mm Hg = millimeter of mercury

John starts with basal analog insulin 10 units at bedtime John gave himself the first injection in the office, using an insulin pen He was provided with a self-titration schedule He was prescribed carvedilol 6.25 mg BID (does not increase blood glucose) He was counseled to perform SMBG fasting and at bedtime He was taken off glimepiride He was taken off SU BID = twice daily; BP = blood pressure; mg = milligrams; SMBG = self-monitored blood glucose.

John BP Check-up Visit At 1-week follow up, John s BP is 156/92 mm Hg His carvedilol dose is increased to 12.5 mg BID His wife is very supportive in helping him make dietary changes He is referred to a dietitian for help with specific food questions He is doing well with insulin pen injections, and has been following his self-titration schedule BID = twice daily; BP = blood pressure; mg = milligram; mm Hg = millimeters of mercury.

John 3-month Checkup Height: 6 2, Weight: 228 lbs, BMI: 29 kg/m 2 BP 130/84 mm Hg, HR 68 bpm Foot and fundoscopy exam: no change since prior visit Labs: A1C: 7.9% Serum creatinine: 2.3 mg/dl Urine albumin : 60 mg/g, LFTs normal Current medications: Sitagliptin, 50 mg QD ASA, 81 mg 50 U/d long-acting insulin analog Benazepril, 40 mg QD Simvastatin, 40 mg QD Escitalopram, 10 mg QD Carvedilol, 12.5 mg BID A1C = glycated hemoglobin A1C; ASA = Aspirin; BID = twice daily; BMI = body mass Index; BP = blood pressure; dl = deciliter; FBG = fasting blood glucose; g = gram; HDL = high density lipoproteins; HR = heart rate; lb = pounds; kg = kilogram; LDL = Low density liproproteins; LFT = liver function test; m 2 = meters square; mg = milligram; ROS = review of systems; SMBG = self blood glucose monitoring; SQ = Subcutaneous; TC = total cholesterol; TG = triglycerides; WNL = within normal limits; QD = once daily; hs = before bed.

John SMBG Log John brought in examples of his SMBG log Time BG (mg/dl) Time BG (mg/dl) Time BG (mg/dl) 8:00 (fasting) 126 7:30 (fasting) 134 8:00 (fasting) 136 1:00 (post-lunch) Missed reading 1:00 (post-lunch) 214 1:00 (post-lunch) 229 5:30 (post-dinner) 210 6:30 (post-dinner) Missed reading 5:30 (post-dinner) 240 9:30 (bedtime) 242 10:00 (bedtime) 219 9:30 (bedtime) 197 BG= blood glucose; dl = deciliter; mg = milligram; SMBG=self-monitoring of blood glucose

John What is the best option? (a) Increase his basal insulin dose (b) Add a rapid-acting insulin with each meal (c) Add rapid acting analog to his largest meal (d) Switch to premix insulin?

Options When Not at Goal with One Injection of Basal Insulin Basal Plus Add prandial insulin at main meal or Switch to Basal/Bolus or Switch to a premixed insulin analog Divide dose in half and give twice daily (breakfast and dinner) after meals if feeding uncertain

John Basal Plus Bolus Mealtime Insulin Use rapid-acting analogs, not regular insulin Easier timing, less postprandial hypoglycemia Can be taken up to 15 minutes after starting to eat May start with 1 injection, at largest meal; however most patients need a dose with each meal 4 units and titrate OR by weight - 0.1 U/kg OR 1 U/15 gms CHO and titrate Titrate to: <140 mg/dl 2 hours post-prandial OR <110 mg/dl next meal or bedtime Stop oral SUs/glinides when prandial insulin is started CHO = carbohydrates; dl = deciliter; kg = kilogram; mg = milligram, SU = sulfonylurea; U = unit.

John 3-month Follow-up Height: 6 2, Weight: 210 lbs, BMI: 27 kg/m 2, BP: 130/78 mm Hg, HR: 80 bpm Foot exam: no change since prior visit Labs: A1C: 6.4%; FPG: 94-100 mg/dl; 2-h PPG: 110-118 mg/dl Serum creatinine: 2.1 mg/dl Urine albumin: 20 mg/g, LFTs normal Current medications: 50 U long-acting analog insulin SQ hs 12 U rapid-acting insulin SQ with breakfast and lunch 15 U rapid-acting insulin SQ with dinner John will follow up in 3 months Benazepril 40 mg QD Simvastatin 40 mg QD Escitalopram 10 mg QD Carvedilol 12.5 mg BID ASA 81 mg QD ASA = Aspirin; A1C = glycated hemoglobin A1C; BID = twice daily; BMI = body mass Index; BP = blood pressure; dl = deciliter; FBG = fasting blood glucose; HDL = high density lipoproteins; g= gram; HR = heart rate; kg = kilogram; m 2 = meter squared; lb = pounds; LDL = low density lipoproteins; LFT = liver function test; mg = milligram; PPG = postprandial glucose; ROS = review of systems; SMBG = self-monitoring of blood glucose; SQ = subcutaneous; TC = total cholesterol; TG = triglycerides; U = units; WNL = within

And Finally: The 5 Keys of Successful Diabetes Self-management 1. Know your metabolic targets (A1C, lipids, blood pressure) 2. Understand how to achieve your metabolic targets 3. Stop smoking 4. Take your medicines 5. Make sure your doctor/provider understands the complexities of diabetes management Unger J. Diabetes Management in Primary Care, 2 nd ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2012.